REGULATORY
PD-1/PD-L1, JAK Drugs to Be Exempt from Spillover Price Cuts: Chuikyo
Japan’s health ministry on March 13 said it intends to exclude PD-1/PD-L1 and JAK inhibitors from the list of drugs subject to the so-called “spillover” from the market expansion re-pricing of other medicines in the same class. The plan was…
To read the full story
Related Article
REGULATORY
- Update: DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
- MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
February 13, 2026
- MHLW Orders Label Revisions for Sulfite-Containing Medical Products
February 13, 2026
- PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
- PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





